CytoDyn Inc. (OTCPK: CYDY)
Health Care · Biotechnology · US
$0.20
-11.89% today · -23.1% 1Y
CytoDyn Inc. (OTCPK: CYDY) operates in the Biotechnology industry within the Health Care sector. The company is valued at $287.21M and employs 14 people.
Over the last twelve months the share price has lost 23.1%, trading between 0.18 and 0.40.
Tweenvest scores CytoDyn Inc. across four factors: quality 16/100, value 81/100. Its strongest factor is value.
CYDY price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $287.21M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -0.03
- Dividend yield
- —
- Beta (5Y)
- 1.50
- 52-week high
- $0.40
- 52-week low
- $0.18
- Avg volume (3M)
- —
- Shares outstanding
- 1.44B
- Employees
- 14
- Next earnings
- —
About CytoDyn Inc.
CytoDyn Inc. functions as a biotechnology enterprise currently in its clinical development phase. The company primarily concentrates on crafting therapies for a variety of medical conditions, leveraging leronlimab – an innovative humanized monoclonal antibody designed to interact with the CCR5 receptor. This experimental drug is being explored for its potential applications in human immunodeficiency virus (HIV), non-alcoholic steatohepatitis (NASH), various oncological diseases, and coronavirus disease (COVID-19). In addition, leronlimab is undergoing a Phase 1b/2 clinical investigation specifically for metastatic triple-negative breast cancer. Established in 2002, and previously operating as RexRay Corporation, CytoDyn Inc. is headquartered in Vancouver, Washington.
- ISIN
- US23283M1018
- Founded
- 2002
- Listed since
- Dec 13, 2006
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| TWi Biotechnology, Inc.TPEX: 6610 | $290.73M | NT$45.05 | -11.49% |
| Lexeo Therapeutics, Inc.NasdaqGM: LXEO | $289.61M | $3.21 | -9.07% |
| Clinuvel Pharmaceuticals LimitedASX: CUV | $287.82M | AU$8.20 | +0.86% |
| Abeona Therapeutics Inc.NasdaqCM: ABEO | $287.64M | $4.96 | -1.39% |
| Eurobio Scientific Société anonymeENXTPA: ALERS | $284.43M | €25.20 | +0.40% |
| Rocket Pharmaceuticals, Inc.NasdaqGM: RCKT | $281.02M | $2.63 | +2.73% |
| Perspective Therapeutics, Inc.NYSEAM: CATX | $280.81M | $2.71 | +10.16% |
| X4 Pharmaceuticals, Inc.NasdaqCM: XFOR | $280.59M | $2.79 | -1.41% |
Figures last refreshed Oct 4, 2026.